Plastic Surgery International / 2018 / Article / Tab 2

Corrigendum

Corrigendum to “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years”

Table 2

Indications for ADM implementation.

Oncologic indicationAesthetic indication
ADMProductBR with ADM (n)BR with no capsular contracture BR with capsular contracture Primary augmentation Secondary augmentation after capsular contracture Secondary augmentation after aesthetic-related complications

HADMEpiflex® / DIZG1513920

PADMStrattice® / LifeCell2168520

BADMTutomesh® / rti surgical1625324

Listing of kind of matrix used, name of product, number of breast reconstructions with certain ADMs, and indications for ADM usage (breast reconstruction (BR) with no capsular contracture, BR with capsular contracture, primary augmentation, secondary augmentation after capsular contracture, or secondary augmentation after aesthetic-related complications including IMF-loss and insufficient implant coverage with breast tissue). Oncologic patients made up 27% of the HADM group, 67% of the PADM group, and 44% of the BADM group; HADM: human ADM, PADM: porcine ADM, and BADM: bovine ADM; denotes no history of radiotherapy; denote history of radiotherapy; denote primary augmentation in cases with large breasts; denote loss of IMF.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.